Coherus Biosciences (8C5) Stock Price & Analysis
8C5 Stock Chart & Stats
- Day’s Range
- EUR 0.78 - EUR 0.78
- 52-Week Range
- EUR 0.78 - EUR 2.19
- Previous Close
- EUR 0.99
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 114.67M
- Enterprise Value
- EUR 165.61M
- Total Cash (Recent Filing)
- EUR 105.31M
- Total Debt (Recent Filing)
- EUR 37.71M
- Price to Earnings (P/E)
- ―
- Beta
- 1.14
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- -0.2
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
LOQTORZI Commercial Growth
LOQTORZI is showing measurable commercial traction, with sequential sales growth, improving patient starts and better treatment duration. If management sustains the guided 10%–15% quarterly growth range, the product can become a more meaningful recurring revenue base.
Operating Cost Discipline
Sustained reductions in R&D and SG&A indicate a leaner operating structure after the divestiture. Continued expense discipline can extend available funding, reduce the scale of future cash needs and improve the earnings impact of commercial growth.
Oncology Pipeline Validation
The interim TREGCHECK results provide early clinical support for tagmokitug and the company’s CCR8-focused immuno-oncology strategy across multiple tumor types. Further validation could broaden the pipeline’s strategic value and create additional product opportunities.
Bears Say
Severe Cash Burn
Large recurring operating and free-cash-flow losses mean the business is not currently self-funding. Even with cost reductions and stated funding through key readouts, continued burn increases dependence on financing, asset proceeds or faster commercial improvement.
Unstable Earnings Base
The sharp revenue contraction and swing from prior profit to substantial losses show limited earnings durability. Deeply negative margins leave little operating leverage today and make future performance highly dependent on successful product scaling and disciplined spending.
Clinical And Regulatory Uncertainty
The oncology strategy depends on converting preliminary efficacy and biomarker signals into mature, reproducible data and eventual regulatory progress. Until that evidence develops, pipeline value remains exposed to changing results, slower development and approval uncertainty.
8C5 FAQ
What was Coherus Biosciences’s price range in the past 12 months?
What is Coherus Biosciences’s market cap?
When is Coherus Biosciences’s upcoming earnings report date?
How were Coherus Biosciences’s earnings last quarter?
Is Coherus Biosciences overvalued?
Does Coherus Biosciences pay dividends?
What is Coherus Biosciences’s EPS estimate?
How many shares outstanding does Coherus Biosciences have?
What happened to Coherus Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Coherus Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Coherus Biosciences Stock Smart Score
Company Description
Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dennis Lanfear
- Employees
- 144
- Website
- www.coherus.com
- Address
- 333 Twin Dolphin Drive, Redwood City, CA, 94065, US
Coherus Biosciences (8C5) Earnings & Revenues
8C5 Earnings Call
Earnings Call SentimentPositive
The call conveys meaningful progress across clinical and commercial fronts: robust enrollment across multiple studies, encouraging early TAGMO signals with biomarker directionality, solid commercial momentum for LOQTORZI (+15% QoQ sales) and sustained cost/liability reductions. Offsetting risks include a sizable quarter-over-quarter cash decline (~ -36.9%), an unachieved $37.5M milestone in Q2, immature clinical datasets that could change post-data cleaning, and ongoing commercial adoption/dosing frictions. On balance, the highlights (pipeline enrollment, early efficacy signals, revenue growth, expense reductions and liability improvements) outweigh the lowlights, though near-term execution and data maturation remain critical.
View all DE:8C5 earnings summaries8C5 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |
